Facilities using these devices must immediately cease their use, segregate them from other stock, and return them to Boston Scientific. Relevant personnel must be notified of this recall.
Organisations should review their DBS checking arrangements, especially prioritizing checks that include the Children's Barred List for those working with children, as part of their compliance with the new definition from September 2026.
Submit bluetongue samples to APHA with forms attached securely on the outside of the parcel to facilitate rapid booking into their digital sample handling system.
Monitor and reassess affected pain and arthritis products, ensuring compliance with safety reporting protocols for products listed with known hidden ingredients.
Consumers should consult healthcare professionals if using this product and report any adverse effects to FDA’s MedWatch Safety Information.
Healthcare providers and manufacturers must now comply with new reporting obligations for adverse reactions associated with the use of Imaavy and ensure adherence to increased compliance requirements for its administration.
Regulatory intelligence teams should review ongoing studies and compliance with postmarketing requirements for the drugs listed, specifically focusing on their deadlines for completion and the nature of the studies required.
Stakeholders should incorporate the device authorization into labeling and signal management protocols to ensure compliance and effective communication regarding its capabilities.
